3,635 results match your criteria Advanced Drug Delivery Reviews[Journal]


Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.

Adv Drug Deliv Rev 2022 Jun 25:114402. Epub 2022 Jun 25.

Lysosomal And Rare Disorders Research And Treatment Center (LDRTC), Fairfax, Virginia, USA.

Lysosomes have a critical role in maintaining normal cellular homeostasis mediated by their involvement in secretion, plasma membrane repair, cell signaling and energy metabolism. Lysosomal storage disorders (LSDs) are a group of approximately 50 rare disorders caused by lysosomal dysfunction that occur due to mutations in a gene of a lysosomal protein. Gaucher disease (GD), an autosomal recessive disorder and one of the most common LSDs, is caused by the deficiency of the lysosomal enzyme glucocerebrosidase (GCase), due to biallelic mutations in the GBA1 gene. Read More

View Article and Full-Text PDF

Sustained delivery approaches to improving adaptive immune responses.

Adv Drug Deliv Rev 2022 Jun 21;187:114401. Epub 2022 Jun 21.

Department of Bioengineering, Stanford University, Stanford 94305, USA; Department of Materials Science & Engineering, Stanford University, Stanford 94305, USA; Department of Pediatrics (Endocrinology), Stanford University, Stanford 94305, USA; ChEM-H Institute, Stanford University, Stanford CA 94305, USA; Woods Institute for the Environment, Stanford University, Stanford, CA 94305, USA. Electronic address:

The immune system is one of the most important, complex biological networks regulating and protecting human health. Its precise modulation can prevent deadly infections and fight cancer. Accordingly, prophylactic vaccines and cancer immunotherapies are some of the most powerful technologies to protect against potential dangers through training of the immune system. Read More

View Article and Full-Text PDF

Therapeutic nanotechnologies for Alzheimer's disease: A critical analysis of recent trends and findings.

Adv Drug Deliv Rev 2022 Jun 20;187:114397. Epub 2022 Jun 20.

Faculté de Pharmacie, Université de Montréal, 2940 Chemin de Polytechnique, Montréal, Québec H3T 1J4, Canada. Electronic address:

Alzheimer's Disease (AD) is an irreversible neurodegenerative disease for which no modifying therapies are presently available. Besides the identification of pathological targets, AD presents numerous clinical and pharmacological challenges such as efficient active delivery to the central nervous system, cell targeting, and long-term dosing. Nanoparticles have been explored to overcome some of these challenges as drug delivery vehicles or drugs themselves. Read More

View Article and Full-Text PDF

Cell-based drug delivery systems and their in vivo fate.

Adv Drug Deliv Rev 2022 Jun 16:114394. Epub 2022 Jun 16.

School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, P. R. China. Electronic address:

Cell-based drug delivery systems (DDSs) have received attention recently because of their unique biological properties and self-powered functions, such as excellent biocompatibility, low immunogenicity, long circulation time, tissue-homingcharacteristics, and ability to cross biological barriers. A variety of cells, including erythrocytes, stem cells, and lymphocytes, have been explored as functional vectors for the loading and delivery of various therapeutic payloads (e.g. Read More

View Article and Full-Text PDF

Microbiome as an immune regulator in health, disease, and therapeutics.

Adv Drug Deliv Rev 2022 Jun 16:114400. Epub 2022 Jun 16.

Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA; Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA. Electronic address:

New discoveries in drugs and drug delivery systems are focused on identifying and delivering a pharmacologically effective agent, potentially targeting a specific molecular component. However, current drug discovery and therapeutic delivery approaches do not necessarily exploit the complex regulatory network of an indispensable microbiota that has been engineered through evolutionary processes in humans or has been altered by environmental exposure or diseases. The human microbiome, in all its complexity, plays an integral role in the maintenance of host functions such as metabolism and immunity. Read More

View Article and Full-Text PDF

Implantable Micro-Light-Emitting Diode (µLED)-based optogenetic interfaces toward human applications.

Adv Drug Deliv Rev 2022 Jun 15;187:114399. Epub 2022 Jun 15.

Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea. Electronic address:

Optogenetics has received wide attention in biomedical fields because of itsadvantages in temporal precision and spatial resolution. Beyond contributions to important advances in fundamental research, optogenetics is inspiring a shift towards new methods of improving human well-being and treating diseases. Soft, flexible and biocompatible systems using µLEDs as a light source have been introduced to realize brain-compatible optogenetic implants, but there are still many technical challenges to overcome before their human applications. Read More

View Article and Full-Text PDF

Repetitive drug delivery using Light-Activated liposomes for potential antimicrobial therapies.

Adv Drug Deliv Rev 2022 Jun 13;187:114395. Epub 2022 Jun 13.

Department of Chemical & Environmental Engineering, University of Cincinnati, Cincinnati, OH 45221, United States.

Overuse or misuse of antibiotics and their residues in the environment results in the emergence and prevalence of drug-resistant bacteria and leads to serious health problems. Notable progress in liposome research has been made in drug delivery and several liposomal drugs have been approved for clinical use owing to its biocompatibility and improved efficacy. Recently, liposomes have been engineered further to release encapsulated drugs on the target of interest in a dose-controlled fashion in response to external stimuli such as light, pH, and heat. Read More

View Article and Full-Text PDF

Novel antimicrobial agents for combating antibiotic-resistant bacteria.

Adv Drug Deliv Rev 2022 Jun 4;187:114378. Epub 2022 Jun 4.

Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia; Department of Microbiology, Monash University, Clayton, Victoria, Australia. Electronic address:

Antibiotic therapy has become increasingly ineffective against bacterial infections due to the rise of resistance. In particular, ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) have caused life-threatening infections in humans and represent a major global health threat due to a high degree of antibiotic resistance. To respond to this urgent call, novel strategies are urgently needed, such as bacteriophages (or phages), phage-encoded enzymes, immunomodulators and monoclonal antibodies. Read More

View Article and Full-Text PDF

Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment.

Adv Drug Deliv Rev 2022 Jun 3;187:114365. Epub 2022 Jun 3.

Department of Chemistry and Biochemistry, University of Texas at El Paso, 500 W University Ave., El Paso, TX 79968, USA; Border Biomedical Research Center, Forensic Science, & Environmental Science and Engineering, University of Texas at El Paso, 500 West University Ave., El Paso, TX 79968, USA. Electronic address:

Cancer immunotherapy has achieved remarkable success over the past decade by modulating patients' own immune systems and unleashing pre-existing immunity. However, only a minority of cancer patients across different cancer types are able to benefit from immunotherapy treatment; moreover, among those small portions of patients with response, intrinsic and acquired resistance remains a persistent challenge. Because the tumor microenvironment (TME) is well recognized to play a critical role in tumor initiation, progression, metastasis, and the suppression of the immune system and responses to immunotherapy, understanding the interactions between the TME and the immune system is a pivotal step in developing novel and efficient cancer immunotherapies. Read More

View Article and Full-Text PDF

Bioactive 2D nanomaterials for neural repair and regeneration.

Adv Drug Deliv Rev 2022 Jun 3;187:114379. Epub 2022 Jun 3.

Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, School of Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200065 PR China. Electronic address:

Biomaterials have provided promising strategies towards improving the functions of injured tissues of the nervous system. Recently, 2D nanomaterials, such as graphene, layered double hydroxides (LDHs), and black phosphorous, which are characterized by ultrathin film structures, have attracted much attention in the fields of neural repair and regeneration. 2D nanomaterials have extraordinary physicochemical properties and excellent biological activities, such as a large surface-area-to-thickness ratio, high levels of adhesion, and adjustable flexibility. Read More

View Article and Full-Text PDF

An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy.

Adv Drug Deliv Rev 2022 Jun 1;187:114380. Epub 2022 Jun 1.

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, PR China. Electronic address:

Effective delivery of therapeutic modality throughout the tumorous nidus plays a crucial role in successful solid tumor treatment. However, conventional nanomedicines based on enhanced permeability and retention (EPR) effect have yielded limited delivery/therapeutic efficiency, due mainly to the heterogeneity of the solid tumor. Leukocytes, which could intrinsically migrate across the vessel wall and crawl through tissue interstitium in a self-deformable manner, have currently emerged as an alternative drug delivery vehicle. Read More

View Article and Full-Text PDF

Peptide-decorated nanocarriers penetrating the blood-brain barrier for imaging and therapy of brain diseases.

Adv Drug Deliv Rev 2022 May 30;187:114362. Epub 2022 May 30.

Center of Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, China; Department of Pharmacology, School of Basic Medical Sciences & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200032, China. Electronic address:

Blood-Brain Barrier (BBB) is one of the most important physiological barriers strictly restricting the substance exchange between blood and brain tissues. While the BBB protects the brain from infections and toxins and maintains brain homeostasis, it is also recognized as the main obstacle to the penetration of therapeutics and imaging agents into the brain. Due to high specificity and affinity, peptides are frequently exploited to decorate nanocarriers across the BBB for diagnosis and/or therapy purposes. Read More

View Article and Full-Text PDF

Engineered microbial systems for advanced drug delivery.

Adv Drug Deliv Rev 2022 May 30;187:114364. Epub 2022 May 30.

NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), National University of Singapore, Singapore; Synthetic Biology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address:

The human body is a natural habitat for a multitude of microorganisms, with bacteria being the major constituent of the microbiota. These bacteria colonize discrete anatomical locations that provide suitable conditions for their survival. Many bacterial species, both symbiotic and pathogenic, interact with the host via biochemical signaling. Read More

View Article and Full-Text PDF

Molecular imaging approaches to facilitate bacteria-mediated cancer therapy.

Adv Drug Deliv Rev 2022 May 30;187:114366. Epub 2022 May 30.

Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea; Department of Nuclear Medicine, Chonnam National University Medical School, Hwasun, Jeonnam, Korea. Electronic address:

Bacteria-mediated cancer therapy is a potential therapeutic strategy for cancer that has unique properties, including broad tumor-targeting ability, various administration routes, the flexibility of delivery, and facilitating the host's immune responses. The molecular imaging of bacteria-mediated cancer therapy allows the therapeutically injected bacteria to be visualized and confirms the accurate delivery of the therapeutic bacteria to the target lesion. Several hurdles make bacteria-specific imaging challenging, including the need to discriminate therapeutic bacterial infection from inflammation or other pathologic lesions. Read More

View Article and Full-Text PDF

Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.

Adv Drug Deliv Rev 2022 May 30;187:114367. Epub 2022 May 30.

Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA; Departments of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA; Departments of Diagnostic Medicine, The University of Texas at Austin, Austin, TX 78712, USA; Departments of Oncology, The University of Texas at Austin, Austin, TX 78712, USA; Departments of Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX 78712, USA; Departments of Imaging Physics, MD Anderson Cancer Center, Houston, TX 77230, USA.

Immunotherapy has become a fourth pillar in the treatment of brain tumors and, when combined with radiation therapy, may improve patient outcomes and reduce the neurotoxicity. As with other combination therapies, the identification of a treatment schedule that maximizes the synergistic effect of radiation- and immune-therapy is a fundamental challenge. Mechanism-based mathematical modeling is one promising approach to systematically investigate therapeutic combinations to maximize positive outcomes within a rigorous framework. Read More

View Article and Full-Text PDF

Micro- and nanocarriers for pain alleviation.

Adv Drug Deliv Rev 2022 May 30;187:114359. Epub 2022 May 30.

Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92296 Châtenay-Malabry, France. Electronic address:

Acute or chronic pain is a major source of impairment in quality of life and affects a substantial part of the population. To date, pain is alleviated by a limited range of treatments with significant toxicity, increased risk of misuse and inconsistent efficacy, owing, in part, to lack of specificity and/or unfavorable pharmacokinetic properties. Thanks to the unique properties of nanoscaled drug carriers, nanomedicine may enhance drug biodistribution and targeting, thus contributing to improved bioavailability and lower off-target toxicity. Read More

View Article and Full-Text PDF

Bacterially mediated drug delivery and therapeutics: Strategies and advancements.

Adv Drug Deliv Rev 2022 May 29;187:114363. Epub 2022 May 29.

State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, Jiangsu, China; Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories Inc, Changzhou 213164, Jiangsu, China; School of Biopharmacy, China Pharmaceutical University, Nanjing 210023, Jiangsu, China. Electronic address:

It was already clinically apparent 150 years ago that bacterial therapy could alleviate diseases. Recently, a burgeoning number of researchers have been using bacterial regimens filled with microbial therapeutic leads to diagnose and treat a wide range of disorders and diseases, including cancers, inflammatory diseases, metabolic disorders and viral infections. Some bacteria that were designed to have low toxicity and high efficiency in drug delivery have been used to treat diseases successfully, especially in tumor therapy in animal models or clinical trials, thanks to the progress of genetic engineering and synthetic bioengineering. Read More

View Article and Full-Text PDF

The in vivo fate and targeting engineering of crossover vesicle-based gene delivery system.

Adv Drug Deliv Rev 2022 May 29;187:114324. Epub 2022 May 29.

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, PR China; Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, PR China; Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, PR China; Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, PR China. Electronic address:

Exosomes and biomimetic vesicles are widely used for gene delivery because of their excellent gene loading capacity and stability and their natural targeting delivery potential. These vesicles take advantages of both cell-based bioactive delivery system and synthetical lipid-derived nanovectors to form crossover characteristics. To further optimize the specific targeting properties of crossover vesicles, studies of their in vivo fate and various engineering approaches including nanobiotechnology are required. Read More

View Article and Full-Text PDF

Nano-bio interactions of 2D molybdenum disulfide.

Adv Drug Deliv Rev 2022 May 27;187:114361. Epub 2022 May 27.

Biomedical Engineering, College of Engineering, Texas A&M University, College Station, TX 77843, USA; Material Science and Engineering, College of Engineering, Texas A&M University, College Station, TX 77843, USA; Center for Remote Health Technologies and Systems, Texas A&M University, College Station, TX 77843, USA; Interdisciplinary Program in Genetics and Genomics, Texas A&M University, College Station, TX 77843, USA. Electronic address:

Two-dimensional (2D) molybdenum disulfide (MoS) is an ultrathin nanomaterial with a high degree of anisotropy, surface-to-volume ratio, chemical functionality and mechanical strength. These properties together enable MoS to emerge as a potent nanomaterial for diverse biomedical applications including drug delivery, regenerative medicine, biosensing and bioelectronics. Thus, understanding the interactions of MoS with its biological interface becomes indispensable. Read More

View Article and Full-Text PDF

Two-dimensional nanomaterials for tumor microenvironment modulation and anticancer therapy.

Adv Drug Deliv Rev 2022 May 28;187:114360. Epub 2022 May 28.

Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia. Electronic address:

The development of two-dimensional (2D) nanomaterials for cancer therapy has attracted increasing attention due to their high specific surface area, unique ultrathin structure, electronic and photonic properties. For biomedical applications, investigations into the family of 2D materials have been sparked by graphene and its derivatives. Many 2D nanomaterials, including layered double hydroxides, transition metal dichalcogenides, nitrides and carbonitrides, black phosphorus nanosheets, and metal-organic framework nanosheets, are extensively explored as cancer theranostic platforms. Read More

View Article and Full-Text PDF

Advances in modular control of CAR-T therapy with adapter-mediated CARs.

Adv Drug Deliv Rev 2022 May 23;187:114358. Epub 2022 May 23.

Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA. Electronic address:

Protein engineering has contributed to successes in the field of T cell-based immunotherapy, including chimeric antigen receptor (CAR) T cell therapy. CAR T cell therapy has become a pillar of cancer immunotherapy, demonstrating clinical effectiveness against B cell malignancies by targeting the B cell antigen CD19. Current gene editing techniques have limited safety controls over CAR T cell activity, which presents a hurdle for control of CAR T cells in patients. Read More

View Article and Full-Text PDF

Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.

Adv Drug Deliv Rev 2022 May 21;187:114357. Epub 2022 May 21.

Department of Chemistry, University of North Carolina Charlotte, Charlotte, NC 28223, USA; The Center for Biomedical Engineering and Science, University of North Carolina Charlotte, Charlotte, NC 28223, USA. Electronic address:

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers due to its aggressiveness and the challenges for early diagnosis and treatment. Recently, nanotechnology has demonstrated relevant strategies to overcome some of the major clinical issues in the treatment of PDAC. This review is focused on the pathological hallmarks of PDAC and the impact of nanotechnology to find solutions. Read More

View Article and Full-Text PDF

Stabilizing vaccines via drying: Quality by design considerations.

Adv Drug Deliv Rev 2022 May 19;187:114313. Epub 2022 May 19.

SSPC, The SFI Research Centre of Pharmaceuticals, Bernal Institute, Department of Chemical Sciences, University of Limerick, Limerick, Ireland. Electronic address:

Pandemics and epidemics are continually challenging human beings' health and imposing major stresses on the societies particularly over the last few decades, when their frequency has increased significantly. Protecting humans from multiple diseases is best achieved through vaccination. However, vaccines thermal instability has always been a hurdle in their widespread application, especially in less developed countries. Read More

View Article and Full-Text PDF

Understanding interactions between biomolecules and two-dimensional nanomaterials using in silico microscopes.

Adv Drug Deliv Rev 2022 Jul 19;186:114336. Epub 2022 May 19.

IBM Thomas J. Watson Research, Yorktown Heights, New York 10598, USA. Electronic address:

Two-dimensional (2D) nanomaterials such as graphene are increasingly used in research and industry for various biomedical applications. Extensive experimental and theoretical studies have revealed that 2D nanomaterials are promising drug delivery vehicles, yet certain materials exhibit toxicity under biological conditions. So far, it is known that 2D nanomaterials possess strong adsorption propensities for biomolecules. Read More

View Article and Full-Text PDF

The effects of protein corona on in vivo fate of nanocarriers.

Adv Drug Deliv Rev 2022 Jul 17;186:114356. Epub 2022 May 17.

School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China. Electronic address:

With the emerging advances in utilizing nanocarriers for biomedical applications, a molecular-level understanding of the in vivo fate of nanocarriers is necessary. After administration into human fluids, nanocarriers can attract proteins onto their surfaces, forming an assembled adsorption layer called protein corona (PC). The formed PC can influence the physicochemical properties and subsequently determine nanocarriers' biological behaviors. Read More

View Article and Full-Text PDF

Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges.

Adv Drug Deliv Rev 2022 Jul 16;186:114326. Epub 2022 May 16.

Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway; Department of Biosciences, University of Oslo, 0316 Oslo, Norway.

There is a large interest in developing nanoparticles and extracellular vesicles for delivery of therapeutics or imaging agents. Regulatory approval of such products requires knowledge about their biodistribution, metabolism and excretion. We here discuss possibilities and challenges of methods used for such studies, which most often are performed after labelling with radioactive isotopes or fluorescent molecules. Read More

View Article and Full-Text PDF

Ultrasound triggered organic mechanoluminescence materials.

Adv Drug Deliv Rev 2022 Jul 15;186:114343. Epub 2022 May 15.

Biomedical Engineering Cockrell School of Engineering, the University of Texas at Austin, Austin, TX 78712, USA. Electronic address:

Ultrasound induced organic mechanoluminescence materials have become one of the focal topics in wireless light sources since they exhibit high spatiotemporal resolution, biocompatibility and excellent tissue penetration depth. These properties promote great potential in ultrahigh sensitive bioimaging with no background noise and noninvasive nanodevices. Recent advances in chemistry, nanotechnology and biomedical research are revolutionizing ultrasound induced organic mechanoluminescence. Read More

View Article and Full-Text PDF

Light-triggered photodynamic nanomedicines for overcoming localized therapeutic efficacy in cancer treatment.

Adv Drug Deliv Rev 2022 Jul 14;186:114344. Epub 2022 May 14.

KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea; Medicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Hwarangno 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea. Electronic address:

Photodynamic nanomedicines have significantly enhanced the therapeutic efficacy of photosensitizers (PSs) by overcoming critical limitations of PSs such as poor water solubility and low tumor accumulation. Furthermore, functional photodynamic nanomedicines have enabled overcoming oxygen depletion during photodynamic therapy (PDT) and tissue light penetration limitation by supplying oxygen or upconverting light in targeted tumor tissues, resulting in providing the potential to overcome biological therapeutic barriers of PDT. Nevertheless, their localized therapeutic effects still remain a huddle for the effective treatment of metastatic- or recurrent tumors. Read More

View Article and Full-Text PDF

Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer.

Adv Drug Deliv Rev 2022 Jul 13;186:114340. Epub 2022 May 13.

Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA. Electronic address:

Research on bacterial membrane vesicles (BMVs) is an emerging topic, and the goal is to address whether BMVs can bring translational tools to improve current therapies. In this review, we provided the updated studies on BMVs including their production, their types, and therapeutic regimens for treating infectious diseases and cancers. We described several platforms of BMVs, such as outer membrane vesicles (OMVs), inner membrane vesicles (IMVs) and double membrane vesicles (DMVs), and those structures were produced from Gram-negative or Gram-positive bacteria. Read More

View Article and Full-Text PDF

Editorial/Preface.

Adv Drug Deliv Rev 2022 Jul 13;186:114345. Epub 2022 May 13.

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, No.11 Zhongguancun Beiyitiao, Beijing 100190, China. Electronic address:

View Article and Full-Text PDF